Current treatment option has shown limited efficacy in patient with HER2+ BC and causes adverse rection and rapid drug resistance, so the urgent requirement is targeted treatment for effective clinical outcome (Yang et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.